| Challenges and recent advances in medulloblastoma therapy V Kumar, V Kumar, T McGuire, DW Coulter, JG Sharp, RI Mahato Trends in pharmacological sciences 38 (12), 1061-1084, 2017 | 79 | 2017 |
| Redox-responsive nanoplatform for codelivery of miR-519c and gemcitabine for pancreatic cancer therapy X Xin, V Kumar, F Lin, V Kumar, R Bhattarai, VR Bhatt, C Tan, RI Mahato Science advances 6 (46), eabd6764, 2020 | 51 | 2020 |
| Design, synthesis and biological evaluation of novel hedgehog inhibitors for treating pancreatic cancer V Kumar, AK Chaudhary, Y Dong, HA Zhong, G Mondal, F Lin, V Kumar, ... Scientific reports 7 (1), 1665, 2017 | 36 | 2017 |
| Impact of miRNA-mRNA profiling and their correlation on medulloblastoma tumorigenesis V Kumar, V Kumar, AK Chaudhary, DW Coulter, T McGuire, RI Mahato Molecular Therapy-Nucleic Acids 12, 490-503, 2018 | 35 | 2018 |
| Therapeutic potential of OMe-PS-miR-29b1 for treating liver fibrosis V Kumar, V Kumar, J Luo, RI Mahato Molecular Therapy 26 (12), 2798-2811, 2018 | 24 | 2018 |
| The contribution of two disulfide bonds in the trypsin binding domain of horsegram (Dolichos biflorus) Bowman-Birk inhibitor to thermal stability and functionality V Kumar, LR Gowda Archives of biochemistry and biophysics 537 (1), 49-61, 2013 | 19 | 2013 |
| The use of micelles to deliver potential hedgehog pathway inhibitor for the treatment of liver fibrosis V Kumar, Y Dong, V Kumar, S Almawash, RI Mahato Theranostics 9 (25), 7537, 2019 | 18 | 2019 |
| Syngeneic tobacco carcinogen–induced mouse lung adenocarcinoma model exhibits PD-L1 expression and high tumor mutational burden LP Stabile, V Kumar, A Gaither-Davis, EH Huang, FP Vendetti, ... JCI insight 6 (3), 2021 | 15 | 2021 |
| Polymeric nanomedicine for overcoming resistance mechanisms in hedgehog and Myc-amplified medulloblastoma V Kumar, Q Wang, B Sethi, F Lin, V Kumar, DW Coulter, Y Dong, ... Biomaterials 278, 121138, 2021 | 14 | 2021 |
| Production of horsegram (Dolichos biflorus) Bowman-Birk inhibitor by an intein mediated protein purification system V Kumar, LR Gowda Protein Expression and Purification 89 (1), 16-24, 2013 | 12 | 2013 |
| A salt-bridge stabilized C-terminal hook is critical for the dimerization of a Bowman Birk inhibitor V Kumar, S Murugeson, N Vithani, B Prakash, LR Gowda Archives of biochemistry and biophysics 566, 15-25, 2015 | 4 | 2015 |
| TWIST1 is a critical downstream target of the HGF/MET pathway and is required for MET driven acquired resistance in oncogene driven lung cancer V Kumar, ZA Yochum, P Devadassan, EHB Huang, E Miller, R Baruwal, ... Oncogene, 1-14, 2024 | | 2024 |
| The TWIST1-p27 signaling pathway is a critical determinant of MET TKI cell cycle arrest and resistance in MET altered non-small cell lung cancer V Kumar, ZA Yochum, P Devadassan, E Huang, E Miller, V Ayyala, ... Cancer Research 83 (7_Supplement), 3853-3853, 2023 | | 2023 |
| TWIST1 inhibition overcomes resistance to tyrosine kinase inhibitors in MET driven non-small cell lung cancer V Kumar, ZA Yochum, P Devadassan, E Huang, E Miller, V Ayyala, ... Cancer Research 82 (12_Supplement), 1091-1091, 2022 | | 2022 |
| Reducing false positive prediction of miRNA target genes with RNA sequencing: Hype or hope V Kumar Journal of Translational Science 7, 1-2, 2020 | | 2020 |
| Targeting vismodegib-resistant medulloblastoma using novel hedgehog pathway inhibitor and miR-29b mimic V Kumar, B Sethi, V Kumar, TR Mcguire, DW Coulter, RI Mahato Cancer Research 79 (13_Supplement), 15-15, 2019 | | 2019 |
| Targeting Small Molecule Inhibitor and microRNA for Medulloblastoma Therapy V Kumar, V Kumar, TR McGuire, DW Coulter, RI Mahato MOLECULAR THERAPY 27 (4), 135-135, 2019 | | 2019 |
Ram I MahatoProfessor and Chair, Department of Pharmaceutical Sciences, University of Nebraska Medical CenterVerified email at unmc.edu
